EAUI yields 2000000.00% · JNJ yields 2.13%● Live data
📍 EAUI pulled ahead of the other in Year 1
Combined, EAUI + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EAUI + JNJ for your $10,000?
EAU Technologies, Inc. develops, manufactures, and markets equipment that uses water electrolysis to create non-toxic cleaning and disinfecting fluids for food safety applications and dairy drinking water in the United States. Its products include Primacide A, a disinfecting and sanitizing fluid that kills bacteria, yeast, molds, viruses, and other organisms; Primacide B, an alkaline based cleaner; and Primacide C, which is used to stabilize acid water. The company's fluids are used in commercial food processing, and organic or non-organic agricultural and consumer products that clean, disinfect, remediate, hydrate, and moisturize. It markets its products primarily for food and beverage processing, dairy production and processing, meat and poultry processing, and agricultural grow-out and processing industries, as well as environmental remediation, medical, seafood processing, and grocery store produce and meat departments. The company was formerly known as Electric Aquagenics Unlimited, Inc. and changed its name to EAU Technologies, Inc. in January 2007. EAU Technologies, Inc. was founded in 1998 and is headquartered in Kennesaw, Georgia.
Full EAUI Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.